Braid: Alberta hit by measles comparison with U.S., but all Canada is an epidemic in waiting
Article content
Alberta does have a serious measles problem, some of it caused by the UCP government's ambiguity about vaccination.
Article content
Article content
But so does nearly everybody else. Vaccination rates are dangerously low across the country. Escaping a big infection cluster like Alberta's is largely dumb luck.
Article content
Article content
The U.S. has 1,288 cases, or so it's said.
Article content
Now, that's a story. Alberta has more measles than a country with 100 times our population.
Article content
The stated American number is almost certainly far too low. Vaccination rates in many states are below Canada's.
Article content
President Donald Trump is busily dismantling national standards and agencies. Who's counting as they lose their jobs?
Article content
Article content
What matters is how we're doing here at home. And it's a dismal picture nearly everywhere, especially for children.
Article content
Article content
Here are vaccination rates by province for the crucial category of kids age seven or under:
Article content
Only Saskatchewan, the vaccination rock star, would pass the 95 per cent target for creating mass immunity and stopping measles cold.
Article content
Alberta vaccination rates rise with age until, by late teens, they're often over 90 per cent. But the most vulnerable are woefully under-protected.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
28 minutes ago
- CTV News
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
The weight-loss drug Wegovy is shown in this undated photo. THE CANADIAN PRESS/handout, Novo Nordisk Canada Inc. Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy. The fall comes after U.S. President Donald Trump on Thursday sent letters to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. That prompted share price declines across the sector. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23 per cent on the day. Novo became Europe's most valuable listed company following the launch of Wegovy in June 2021. But its shares have plunged by more than two-thirds since peaking last year on concerns the drugmaker is losing ground in the obesity drug race. 'The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices,' Novo said in an emailed statement. Novo's shares were 4.9 per cent lower at 08:39 GMT. Friday's drop brings this week's losses to more than 30 per cent - the stock's worst-ever weekly fall. The European healthcare index .SXDP was down 1.6 per cent, its lowest since April. 'Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade,' said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly LLY.N and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. 'This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump,' Hansen said. (Reporting by Anna Pruchnicka, Elviira Luoma, Jacob Gronholt-Pedersen and Louise Breusch Rasmussen. Editing by Amanda Cooper and Mark Potter)
CTV News
14 hours ago
- CTV News
Trump pressures 17 pharma CEOs to cut U.S. drug prices
Pills spill in an arrangement photo of prescription Oxycodone in New York. (AP Photo/Mark Lennihan, File) U.S. President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about two per cent each, while the NYSE Arca Pharmaceutical Index fell three per cent on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until Sept. 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis, AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said. Jeff Mason, Nandita Bose, Patrick Wingrove, Reuters
Toronto Star
16 hours ago
- Toronto Star
Trump revives the Presidential Fitness Test for American schoolchildren
WASHINGTON (AP) — President Donald Trump on Thursday reestablished the Presidential Fitness Test for American schoolchildren, a program created in 1966 to help interest young people in following healthy, active lifestyles. Children had to run and perform situps, pullups or pushups and a sit-and-reach test, but the program changed in 2012 during the Obama administration to focus more on individual health than athletic feats.
